Lin Shen is a Rheumatology/Immunology physician. ClinicalTrials.gov lists 135 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
400 Parnassus Ave # U384
San Francisco, CA 941432202
Telephone
415-353-2497Registry record last updated 27 Dec 2018.
Clinical trials
- A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC
Sponsor: Nanjing Leads Biolabs Co.,Ltd
- A Clinical Study GK01 Cell Injection in Subjects With Advanced Lung Cancer
Sponsor: Beijing Geekgene Technology Co., LTD
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20251 payment
- ABBVIE INC.Program year20243 payments
- Janssen Pharmaceuticals, IncProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
52%Corticosteroid52%Prednisone100%Part D<11 patientsCancer & immunology
26%Folate Analog Metabolic Inhibitor26%Methotrexate100%Part D<11 patientsMusculoskeletal
22%Xanthine oxidase inhibitor22%Allopurinol100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2022–2023 per NIH RePORTER. The latest:
- Dissecting the interactions between TCR signaling strength and inhibitory pathways
University of California, San Francisco
FY2023$44,118K08AI171160 - Dissecting the interactions between TCR signaling strength and inhibitory pathways
University of California, San Francisco
FY2022$197,748K08AI171160
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”